

# Michael A Morse

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5136366/publications.pdf>

Version: 2024-02-01

211  
papers

11,222  
citations

61984

43  
h-index

31849

101  
g-index

218  
all docs

218  
docs citations

218  
times ranked

14730  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1182-1191.	10.7	2,058
2	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 883-895.	10.7	1,091
3	A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. <i>Journal of Translational Medicine</i> , 2005, 3, 9.	4.4	870
4	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1590-1598.	10.7	594
5	Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. <i>Nature Biotechnology</i> , 1998, 16, 364-369.	17.5	383
6	Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. <i>Blood</i> , 2008, 112, 610-618.	1.4	282
7	A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. <i>Clinical Cancer Research</i> , 1999, 5, 1331-8.	7.0	220
8	Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the Pancreas. <i>Annals of Surgical Oncology</i> , 2001, 8, 758-765.	1.5	203
9	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>Journal of Clinical Oncology</i> , 2019, 37, 1608-1616.	1.6	185
10	Induction of Tumor-Specific Cytotoxic T Lymphocytes in Cancer Patients by Autologous Tumor RNA-Transfected Dendritic Cells. <i>Annals of Surgery</i> , 2002, 235, 540-549.	4.2	177
11	Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues. <i>Drug Design, Development and Therapy</i> , 2015, 9, 5075.	4.3	160
12	Immunotherapy with Autologous, Human Dendritic Cells Transfected with Carcinoembryonic Antigen mRNA. <i>Cancer Investigation</i> , 2003, 21, 341-349.	1.3	159
13	Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE) Tj ETQq1 1 0.784014 rgBT 1.0 overlo	1.4	150
14	Induction of carcinoembryonic antigen (cea)-specific cytotoxic t-lymphocyte responsesIn vitro using autologous dendritic cells loaded with cea peptide or cea rna in patients with metastatic malignancies expressing cea. <i>International Journal of Cancer</i> , 1999, 82, 121-124.	5.1	151
15	Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4073-4073.	1.6	133
16	A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon- $\gamma$ treatment. <i>Blood</i> , 2000, 96, 3499-3504.	1.4	131
17	Phase I Study Utilizing a Novel Antigen-Presenting Cell-Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 4844-4853.	7.0	129
18	Phase I Study of Immunization with Dendritic Cells Modified with Fowlpox Encoding Carcinoembryonic Antigen and Costimulatory Molecules. <i>Clinical Cancer Research</i> , 2005, 11, 3017-3024.	7.0	127

#	ARTICLE	IF	CITATIONS
19	Complete Response to Neoadjuvant Chemoradiation for Rectal Cancer Does Not Influence Survival. <i>Annals of Surgical Oncology</i> , 2001, 8, 801-806.	1.5	122
20	Preoperative Mobilization of Circulating Dendritic Cells by Flt3 Ligand Administration to Patients With Metastatic Colon Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 3883-3893.	1.6	120
21	A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer. <i>Annals of Surgery</i> , 2013, 258, 879-886.	4.2	111
22	Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 652-662.	1.4	106
23	An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. <i>Journal of Clinical Investigation</i> , 2010, 120, 3234-3241.	8.2	98
24	Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 239-247.	3.8	96
25	Vaccine Therapies for Cancer: Then and Now. <i>Targeted Oncology</i> , 2021, 16, 121-152.	3.6	90
26	Generation of Dendritic Cells In Vitro From Peripheral Blood Mononuclear Cells With Granulocyte-Macrophage-Colony-Stimulating Factor, Interleukin-4, and Tumor Necrosis Factor- $\alpha$ for Use in Cancer Immunotherapy. <i>Annals of Surgery</i> , 1997, 226, 6-16.	4.2	90
27	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1533-1544.	4.2	89
28	Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2020, 25, 33-45.	3.7	87
29	The Feasibility and Safety of Immunotherapy with Dendritic Cells Loaded with CEA mRNA Following Neoadjuvant Chemoradiotherapy and Resection of Pancreatic Cancer. <i>International Journal of Gastrointestinal Cancer</i> , 2002, 32, 1-6.	0.4	82
30	Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. <i>Onc Immunology</i> , 2015, 4, e1026529.	4.6	79
31	Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with <sup>177</sup> Lu-Dotatate: an analysis of the NETTER-1 study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2372-2382.	6.4	79
32	Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition. <i>Journal of Translational Medicine</i> , 2012, 10, 28.	4.4	77
33	Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1293-1301.	4.2	76
34	Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1453-1461.	3.7	75
35	Enumerating Antigen-Specific T-Cell Responses in Peripheral Blood. <i>Journal of Immunotherapy</i> , 2005, 28, 63-72.	2.4	70
36	Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas. <i>Clinical Colorectal Cancer</i> , 2016, 15, 345-351.	2.3	67

#	ARTICLE	IF	CITATIONS
37	A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study. <i>Clinical and Translational Oncology</i> , 2019, 21, 489-498.	2.4	65
38	A Blueprint to Advance Colorectal Cancer Immunotherapies. <i>Cancer Immunology Research</i> , 2017, 5, 942-949.	3.4	63
39	Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. <i>Clinical Cancer Research</i> , 2017, 23, 5066-5073.	7.0	62
40	Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. <i>Clinical Cancer Research</i> , 2019, 25, 2725-2736.	7.0	50
41	Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142.. <i>Journal of Clinical Oncology</i> , 2017, 35, 519-519.	1.6	49
42	Immunoregulatory T cells in cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2002, 2, 827-834.	3.1	48
43	Recent developments in therapeutic cancer vaccines. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 108-113.	4.3	48
44	XIAP Regulation by MNK Links MAPK and NF $\kappa$ B Signaling to Determine an Aggressive Breast Cancer Phenotype. <i>Cancer Research</i> , 2018, 78, 1726-1738.	0.9	45
45	Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. <i>Clinical Cancer Research</i> , 2019, 25, 1494-1504.	7.0	45
46	Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 977-987.	4.2	44
47	Nicosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy. <i>Biochemical Journal</i> , 2019, 476, 535-546.	3.7	44
48	Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer. <i>Expert Opinion on Biological Therapy</i> , 2009, 9, 331-339.	3.1	43
49	Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.. <i>Journal of Clinical Oncology</i> , 2018, 36, 553-553.	1.6	43
50	Induction of Primary, Human Antigen-Specific Cytotoxic T Lymphocytes In Vitro Using Dendritic Cells Pulsed with Peptides. <i>Journal of Immunotherapy</i> , 1998, 21, 32-40.	2.4	42
51	Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2. <i>Journal of Translational Medicine</i> , 2007, 5, 42.	4.4	42
52	Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142.. <i>Journal of Clinical Oncology</i> , 2018, 36, 554-554.	1.6	39
53	The Role of IL-13 in the Generation of Dendritic Cells in Vitro. <i>Journal of Immunotherapy</i> , 1999, 22, 506-513.	2.4	38
54	Effect of the vaccine Ad5 [E1-, E2b-]-CEA(6D) on CEA-directed CMI responses in patients with advanced CEA-expressing malignancies in a phase I/II clinical trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2585-2585.	1.6	38

#	ARTICLE	IF	CITATIONS
55	Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.. Journal of Clinical Oncology, 2015, 33, 7503-7503.	1.6	38
56	CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. Expert Review of Vaccines, 2011, 10, 733-742.	4.4	36
57	A Phase I-II Study Using Rixin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. Molecular Therapy - Oncolytics, 2019, 12, 56-67.	4.4	36
58	Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.. Journal of Clinical Oncology, 2016, 34, 4501-4501.	1.6	36
59	MHC Class II-Presented Tumor Antigens Identified in Ovarian Cancer by Immunoproteomic Analysis Are Targets for T-Cell Responses against Breast and Ovarian Cancer. Clinical Cancer Research, 2011, 17, 3408-3419.	7.0	35
60	Dendritic cell maturation in active immunotherapy strategies. Expert Opinion on Biological Therapy, 2002, 2, 35-43.	3.1	33
61	The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. Journal of Neuro-Oncology, 2003, 64, 161-176.	2.9	33
62	Checkpoint blockade in combination with cancer vaccines. Vaccine, 2015, 33, 7377-7385.	3.8	33
63	Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. Current Treatment Options in Oncology, 2016, 17, 41.	3.0	33
64	Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE) Tj ETQq0 0 0 rgBT, Overlooked 10 Tf 50	1.0	31
65	Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. Current Opinion in Molecular Therapeutics, 2005, 7, 588-97.	2.8	32
66	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM. Clinical Genitourinary Cancer, 2017, 15, 31-41.e4.	1.9	31
67	Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. , 2017, 5, 102.		31
68	Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and ±PD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. Clinical Cancer Research, 2020, 26, 4670-4681.	7.0	31
69	Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.. Journal of Clinical Oncology, 2019, 37, 635-635.	1.6	31
70	Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratio. , 2020, 8, e001662.		28
71	DC-CIK as a widely applicable cancer immunotherapy. Expert Opinion on Biological Therapy, 2020, 20, 601-607.	3.1	28
72	Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity. , 2022, 10, e003717.		27

#	ARTICLE	IF	CITATIONS
73	HER2 Dendritic Cell Vaccines. <i>Clinical Breast Cancer</i> , 2003, 3, S164-S172.	2.4	26
74	The role of external beam radiotherapy in the treatment of hepatocellular cancer. <i>Cancer</i> , 2018, 124, 3476-3489.	4.1	26
75	Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. <i>European Heart Journal</i> , 2016, 37, ehv611.	2.2	25
76	Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy. <i>Onc Immunology</i> , 2017, 6, e1264563.	4.6	23
77	Long-Term Outcomes of 125 Patients With Metastatic Pheochromocytoma or Paraganglioma Treated With 131-I MIBG. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e494-e501.	3.6	23
78	Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1941-1951.	4.2	22
79	Whole Recombinant <i>Saccharomyces cerevisiae</i> Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial. <i>Journal of Immunotherapy</i> , 2018, 41, 141-150.	2.4	21
80	Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors. <i>International Journal of Hyperthermia</i> , 2019, 36, 74-82.	2.5	21
81	A year of successful cancer vaccines points to a path forward. <i>Current Opinion in Molecular Therapeutics</i> , 2010, 12, 11-3.	2.8	21
82	A phase 2, randomized trial of GVAX pancreas and CRS-207 immunotherapy versus GVAX alone in patients with metastatic pancreatic adenocarcinoma: Updated results.. <i>Journal of Clinical Oncology</i> , 2014, 32, 177-177.	1.6	20
83	Current status of adoptive immunotherapy of malignancies. <i>Expert Opinion on Biological Therapy</i> , 2002, 2, 237-247.	3.1	19
84	Expression of X-Linked Inhibitor of Apoptosis Protein (XIAP) in Breast Cancer Is Associated with Shorter Survival and Resistance to Chemotherapy. <i>Cancers</i> , 2021, 13, 2807.	3.7	19
85	MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response. <i>Journal of Proteomics</i> , 2011, 74, 728-743.	2.4	18
86	Heat shock protein 90-targeted photodynamic therapy enables treatment of subcutaneous and visceral tumors. <i>Communications Biology</i> , 2020, 3, 226.	4.4	18
87	Synergism from combined immunologic and pharmacologic inhibition of HER2 <i>in vivo</i> . <i>International Journal of Cancer</i> , 2010, 126, 2893-2903.	5.1	17
88	Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibition. <i>Onc Immunology</i> , 2017, 6, e1315495.	4.6	17
89	Dendritic Cell Recovery Following Nonmyeloablative Allogeneic Stem Cell Transplants. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 659-668.	1.8	16
90	Depletion of Human Regulatory T Cells. <i>Methods in Molecular Biology</i> , 2011, 707, 219-231.	0.9	16

#	ARTICLE	IF	CITATIONS
91	Immunologic Targeting of FOXP3 in Inflammatory Breast Cancer Cells. PLoS ONE, 2013, 8, e53150.	2.5	16
92	Improved Time to Progression for Transarterial Chemoembolization Compared With Transarterial Embolization for Patients With Unresectable Hepatocellular Carcinoma. Clinical Colorectal Cancer, 2012, 11, 185-190.	2.3	15
93	<i>In Vivo</i> Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior. Clinical Cancer Research, 2017, 23, 7531-7542.	7.0	15
94	Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer. Frontiers in Oncology, 2018, 8, 305.	2.8	15
95	Adoptive immunotherapy with autologous T-cell infusions reduces opioid requirements in advanced cancer patients. Pain, 2020, 161, 127-134.	4.2	15
96	DNA and RNA Modified Dendritic Cell Vaccines. World Journal of Surgery, 2002, 26, 819-825.	1.6	14
97	How does the immune system attack cancer?. Current Problems in Surgery, 2004, 41, 15-132.	1.1	14
98	Novel Recombinant Alphaviral and Adenoviral Vectors for Cancer Immunotherapy. Seminars in Oncology, 2012, 39, 305-310.	2.2	14
99	Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. Breast Cancer Research, 2018, 20, 90.	5.0	14
100	Tumor profiling of biliary tract carcinomas to reveal distinct molecular alterations and potential therapeutic targets.. Journal of Clinical Oncology, 2015, 33, 285-285.	1.6	14
101	The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion. Oncotarget, 2015, 6, 41350-41359.	1.8	14
102	Combining cancer vaccines with chemotherapy. Expert Opinion on Pharmacotherapy, 2005, 6, 2813-2820.	1.8	13
103	A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial). Cancer Chemotherapy and Pharmacology, 2019, 84, 909-917.	2.3	13
104	Blood microbiota diversity determines response of advanced colorectal cancer to chemotherapy combined with adoptive T cell immunotherapy. Oncoimmunology, 2021, 10, 1976953.	4.6	13
105	Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer. Oncologist, 2021, 26, 465-e917.	3.7	13
106	Nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Five-year follow-up from CheckMate 142.. Journal of Clinical Oncology, 2022, 40, 3510-3510.	1.6	13
107	A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 577-584.	2.3	12
108	Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with <sup>131</sup> I-MIBG. Journal of Nuclear Medicine, 2018, 59, 1708-1713.	5.0	12

#	ARTICLE	IF	CITATIONS
109	Current Immunotherapeutic Strategies in Colon Cancer. <i>Surgical Oncology Clinics of North America</i> , 2007, 16, 873-900.	1.5	11
110	Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. <i>Immunologic Research</i> , 2011, 49, 235-247.	2.9	11
111	A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4031-4031.	1.6	10
112	Phase I/II, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) as monotherapy or combined with ipilimumab in advanced or metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3114-TPS3114.	1.6	10
113	Checkmate 032: Nivolumab (N) alone or in combination with ipilimumab (I) for the treatment of recurrent small cell lung cancer (SCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 100-100.	1.6	10
114	Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 414-414.	1.6	10
115	Virus-based therapies for colon cancer. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 1627-1633.	3.1	9
116	Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 391-397.	0.5	9
117	A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. <i>BMC Cancer</i> , 2019, 19, 1032.	2.6	9
118	Differential Diagnosis of Diarrhea in Patients With Neuroendocrine Tumors. <i>Pancreas</i> , 2020, 49, 1123-1130.	1.1	9
119	Discovering pathways in the tumor microenvironment important for recurrence-free survival in patients with colorectal liver metastasis.. <i>Journal of Clinical Oncology</i> , 2012, 30, 480-480.	1.6	9
120	Phase I study of pazopanib plus TH-302 in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 611-619.	2.3	8
121	CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 365-372.	2.3	8
122	Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growth. <i>Immunotherapy</i> , 2019, 11, 953-966.	2.0	8
123	Functional CD3+CD8+PD1 <sup>hi</sup> T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast. <i>Clinical Breast Cancer</i> , 2019, 19, e617-e623.	2.4	8
124	<p>&lt;p>Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study&lt;p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 6607-6614.	1.9	8
125	Interim safety and efficacy analysis of a phase II, randomized study of GVAX pancreas and CRS-207 immunotherapy in patients with metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4040-4040.	1.6	8
126	Technology evaluation: Regin-G, Epeius Biotechnologies. <i>Current Opinion in Molecular Therapeutics</i> , 2005, 7, 164-9.	2.8	8



#	ARTICLE	IF	CITATIONS
127	Surrogate markers of response to cancer immunotherapy. Expert Opinion on Biological Therapy, 2001, 1, 153-158.	3.1	7
128	Phase Ib/II study of pembrolizumab with lanreotide depot for advanced, progressive gastroenteropancreatic neuroendocrine tumors (PLANET).. Journal of Clinical Oncology, 2021, 39, 369-369.	1.6	7
129	Title is missing!. Journal of Neuro-Oncology, 2003, 64, 161-176.	2.9	6
130	Adjuvant Therapy of Colon Cancer: Current Status and Future Developments. Clinics in Colon and Rectal Surgery, 2005, 18, 224-231.	1.1	5
131	Supportive Care in the Management of Colon Cancer. Supportive Cancer Therapy, 2006, 3, 158-170.	0.3	5
132	Prospective randomized comparative study on rivaroxaban and LMWH for prophylaxis of post-apheresis thrombosis in adoptive T cell immunotherapy cancer patients. Journal of Thrombosis and Thrombolysis, 2019, 47, 505-511.	2.1	5
133	Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2016, 34, TPS3103-TPS3103.	1.6	5
134	Concordance of DNA mismatch repair deficient (dMMR)/microsatellite instability (MSI) assessment by local and central testing in patients with metastatic CRC (mCRC) receiving nivolumab (nivo) in CheckMate 142 study.. Journal of Clinical Oncology, 2017, 35, 3548-3548.	1.6	5
135	Immunotherapy of surgical malignancies. Current Problems in Surgery, 2004, 41, 15-132.	1.1	5
136	Dendritic cell-based approaches to cancer immunotherapy. Expert Opinion on Investigational Drugs, 1998, 7, 1617-1627.	4.1	4
137	Surrogate Markers of Effective Anti-Tumor Immunity. Annals of Surgical Oncology, 2001, 8, 190-191.	1.5	4
138	Preparation of Peptide-Loaded Dendritic Cells for Cancer Immunotherapy. Molecular Biotechnology, 2003, 25, 95-100.	2.4	4
139	Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes. , 2014, 2, 20.		4
140	Percutaneous biliary drainage catheter insertion in patients with extensive hepatic metastatic tumor burden. Journal of Gastrointestinal Oncology, 2016, 7, 875-881.	1.4	4
141	Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 3557-3564.	7.0	4
142	Effect of oral cyclophosphamide on the immunogenicity of DPX-Survivac in ovarian cancer patients: Results of a phase I study.. Journal of Clinical Oncology, 2013, 31, 3030-3030.	1.6	4
143	High-dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).. Journal of Clinical Oncology, 2014, 32, 4523-4523.	1.6	4
144	Effect of alphavirus vaccine encoding HER2 during concurrent anti-HER2 therapies on induction of oligoclonal T cell and antibody responses against HER2.. Journal of Clinical Oncology, 2015, 33, 3081-3081.	1.6	4

#	ARTICLE	IF	CITATIONS
145	Phase Ib study of cabozantinib plus panitumumab in KRAS wild-type (WT) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 3548-3548.	1.6	4
146	Sequential administration of high-dose interleukin-2 and ipilimumab in patients with metastatic melanoma.. Journal of Clinical Oncology, 2016, 34, e21041-e21041.	1.6	4
147	Predictive significance of T cell subset changes during ex vivo generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancer. Oncology Letters, 2019, 18, 5717-5724.	1.8	4
148	Biomarkers and Correlative Endpoints for Immunotherapy Trials: What Can We Learn in Lung Cancer from Other Tumor Types?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e287-e293.	3.8	4
149	CEA loaded dendritic cell vaccines. Cancer Chemotherapy and Biological Response Modifiers, 2002, 20, 385-90.	0.5	4
150	Educational Review Cellular and Biological Therapies of Gastrointestinal Tumors: Overview of Clinical Trials. Annals of Surgical Oncology, 1999, 6, 218-223.	1.5	3
151	Designing effective vaccines for colorectal cancer. Immunotherapy, 2014, 6, 913-926.	2.0	3
152	Immunotherapy for Resected Pulmonary Metastases. Thoracic Surgery Clinics, 2016, 26, 69-78.	1.0	3
153	Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome. Cancer Management and Research, 2020, Volume 12, 9713-9719.	1.9	3
154	Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex: A case report and literature review. Molecular and Clinical Oncology, 2021, 15, 186.	1.0	3
155	Changes in Peripheral Blood Regulatory T Cells and IL-6 and IL-10 Levels Predict Response of Pediatric Medulloblastoma and Germ Cell Tumors With Residual or Disseminated Disease to Craniospinal Irradiation. International Journal of Radiation Oncology Biology Physics, 2021, 111, 479-490.	0.8	3
156	Effect of the loss of the type III TGF $\beta$ 2 receptor during tumor progression on tumor microenvironment: Preclinical development of TGF $\beta$ 2 inhibition and TGF $\beta$ 2-related biomarkers to enhance immunotherapy efficacy.. Journal of Clinical Oncology, 2012, 30, 10563-10563.	1.6	3
157	Immunotherapeutic treatment of metastatic colorectal cancer using ETBX-011.. Journal of Clinical Oncology, 2014, 32, 3093-3093.	1.6	3
158	Improved median overall survival (OS) in patients with metastatic melanoma (mM) treated with high-dose (HD) IL-2: Analysis of the PROCLAIM 2007-2012 national registry.. Journal of Clinical Oncology, 2014, 32, 9054-9054.	1.6	3
159	High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).. Journal of Clinical Oncology, 2015, 33, 423-423.	1.6	3
160	Ensituximab (E) in patients (pts) with refractory metastatic colorectal cancer (mCRC): Results of a phase I/II clinical trial.. Journal of Clinical Oncology, 2017, 35, 3081-3081.	1.6	3
161	A phase I/II trial of cabozantinib (C) with or without panitumumab (P) in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Clinical outcomes in pts with MET amplification (amp) detected in blood.. Journal of Clinical Oncology, 2018, 36, 3555-3555.	1.6	3
162	A phase I safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers.. Journal of Clinical Oncology, 2012, 30, 2517-2517.	1.6	3

#	ARTICLE	IF	CITATIONS
163	A phase II therapeutic, open label, multi-center clinical trial of NPC-1C, a chimeric monoclonal antibody (mAb), in adults with chemotherapy refractory metastatic colorectal cancer (mCRC), initial results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 500-500.	1.6	3
164	Optimizing Dendritic Cell Function by Genetic Modification. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1198-1199.	6.3	2
165	Abstract CT111: Results of a phase 1 dose escalation study of ERY974, an anti-glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors. <i>Cancer Research</i> , 2021, 81, CT111-CT111.	0.9	2
166	A phase I/IIA safety study of NPC-1C: A novel, therapeutic antibody to treat pancreas and colorectal cancers.. <i>Journal of Clinical Oncology</i> , 2012, 30, 233-233.	1.6	2
167	High-dose interleukin-2 registry, PROCLAIM: Modern data on toxicities and outcomes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 430-430.	1.6	2
168	Safety, immunogenicity, and clinical activity of the immunotherapeutic vaccine, DPX-Survivac, in a Phase 1/1b trial of women with ovarian, fallopian tube, or peritoneal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3072-3072.	1.6	2
169	Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL).. <i>Journal of Clinical Oncology</i> , 2016, 34, e15013-e15013.	1.6	2
170	Exploring telotristat ethyl's antiproliferative effects in patients with carcinoid syndrome (TELEACE): A real-world observational study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 618-618.	1.6	2
171	HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 217-226.	4.1	2
172	Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen (CEA), in patients with advanced gastrointestinal (GI) adenocarcinomas.. <i>Journal of Clinical Oncology</i> , 2016, 34, 320-320.	1.6	2
173	Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 490-490.	1.6	1
174	Phase I/1b clinical and immunologic assessment of immunotherapeutic vaccine, DPX-Survivac in women with ovarian, Fallopian tube, or peritoneal cancer (OC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5555-5555.	1.6	1
175	A phase II multicenter study of the chimeric monoclonal antibody NEO102 (N) in adults with refractory colorectal cancer (CC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e14013-e14013.	1.6	1
176	A phase I/II multicenter study of the chimeric monoclonal antibody NEO102 (NPC-1C) in adults with refractory pancreatic (PC) and colorectal cancer (CC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 240-240.	1.6	1
177	A phase IIb, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS489-TPS489.	1.6	1
178	A multicenter randomized phase II study of NPC-1C (N) in combination with gemcitabine (G) and nab-paclitaxel (A) versus G and A alone in patients with metastatic or locally advanced pancreatic cancer (PC) previously treated with folfox (F).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS499-TPS499.	1.6	1
179	Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).. <i>Journal of Clinical Oncology</i> , 2016, 34, 511-511.	1.6	1
180	X-TRAP: Phase I/II study of capecitabine (X) plus ziv-aflibercept (TRAP) in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 687-687.	1.6	1

#	ARTICLE	IF	CITATIONS
181	A phase II multicenter study evaluating combination immunotherapy with pembrolizumab and peginterferon alfa-2b for advanced cholangiocarcinoma.. Journal of Clinical Oncology, 2017, 35, TPS507-TPS507.	1.6	1
182	A molecular profile of colorectal cancer to guide prognosis and therapy after resection of primary or metastatic disease.. Journal of Clinical Oncology, 2013, 31, 339-339.	1.6	1
183	A phase II study of NPC-1C: A novel therapeutic monoclonal antibody (mab) to treat pancreatic (P) and colorectal (CR) cancers.. Journal of Clinical Oncology, 2013, 31, 3070-3070.	1.6	1
184	A phase Ib/IIa study of NEO-102: A therapeutic antibody to treat pancreatic and colorectal cancers.. Journal of Clinical Oncology, 2014, 32, 243-243.	1.6	1
185	High dose interleukin-2 and response in 944 patients with metastatic renal cell cancer (RCC): Data from the PROCLAIM registry.. Journal of Clinical Oncology, 2018, 36, 624-624.	1.6	1
186	Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM.. Journal of Clinical Oncology, 2018, 36, 4578-4578.	1.6	1
187	Real-world treatment patterns and survival in patients (pts) with hepatocellular carcinoma in the United States.. Journal of Clinical Oncology, 2020, 38, 519-519.	1.6	1
188	Abstract P1-04-07: Xiap expression is associated with infiltration of cd163+ tumor-associated macrophages in the tumor micro-environment of inflammatory breast cancer. Cancer Research, 2022, 82, P1-04-07-P1-04-07.	0.9	1
189	Dendritic Cell-Based Vaccines in Cancer. American Journal of Cancer, 2002, 1, 313-322.	0.4	0
190	38th Annual Meeting of the American Society of Clinical Oncology. Expert Opinion on Emerging Drugs, 2002, 7, 335-338.	2.4	0
191	Editorial Board Focus " February 2007. Expert Opinion on Biological Therapy, 2007, 7, 157-160.	3.1	0
192	Advances in immunotherapy for colorectal malignancies. Current Colorectal Cancer Reports, 2008, 4, 177-183.	0.5	0
193	Comment regarding benefit in phase 1 oncology trials. Clinical Trials, 2008, 5, 626-626.	1.6	0
194	Immunotherapy in Gastrointestinal Malignancies. , 2016, , 27-69.		0
195	The Outlook for Immune Checkpoint Targeting Strategies in Colorectal Cancer. Current Colorectal Cancer Reports, 2016, 12, 51-56.	0.5	0
196	RNA-Transfected Dendritic Cells as Immunogens. , 2002, , 199-203.		0
197	Recent areas of development for dendritic cell vaccines. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 339-350.	0.5	0
198	Predictive and prognostic markers of recurrence after resection of primary or metastatic colorectal cancer.. Journal of Clinical Oncology, 2012, 30, 447-447.	1.6	0

#	ARTICLE	IF	CITATIONS
199	Effect of the novel therapeutic cancer vaccine formulation DPX-0907 on multifunctional T-cell responses in ovarian, breast, and prostate cancer patients.. Journal of Clinical Oncology, 2012, 30, 2588-2588.	1.6	0
200	Ad5 immunity after multiple safe, homologous immunizations against tumor-associated antigens with new recombinant Ad5 vector.. Journal of Clinical Oncology, 2012, 30, 85-85.	1.6	0
201	A phase Ib/IIa study of NEO-102: A therapeutic antibody for the treatment of advanced pancreatic and colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 3072-3072.	1.6	0
202	A phase 2b, randomized, controlled, multicenter, open-label study of the efficacy and immune response of GVAX pancreas vaccine and CRS-207 compared to chemotherapy or to CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study).. Journal of Clinical Oncology, 2014, 32, TPS4159-TPS4159.	1.6	0
203	Molecular profiling of bile duct and gallbladder cancer to identify different therapeutic options.. Journal of Clinical Oncology, 2014, 32, 4097-4097.	1.6	0
204	Functional genomic screens and identification of signaling pathways in oxaliplatin-resistance in colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 3611-3611.	1.6	0
205	Overall survival of metastatic melanoma (mM) treated with high dose IL-2 (HD IL-2) followed by anti-CTLA4 (IPI) and/or anti-PD-1/PDL1 (aPD1) therapy: Analysis of the prospective cohort of the PROCLAIM national registry.. Journal of Clinical Oncology, 2015, 33, e20071-e20071.	1.6	0
206	Impact of targeted therapy (TT) on survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2): Analysis of the PROCLAIMHD IL-2 National Registry.. Journal of Clinical Oncology, 2015, 33, e15609-e15609.	1.6	0
207	Update on the overall survival of patients with metastatic melanoma treated with immune checkpoint blockade following initial treatment with HD IL-2.. Journal of Clinical Oncology, 2016, 34, e21039-e21039.	1.6	0
208	Extension of overall survival in patients with metastatic renal cell carcinoma who received HD IL-2 followed by targeted therapy and/or immune checkpoint blockade from the PROCLAIM registry.. Journal of Clinical Oncology, 2016, 34, 4548-4548.	1.6	0
209	A phase 2 study of NEO-102 (ensituximab), a novel chimeric monoclonal antibody, in adult patients (pts) with unresectable, metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 3080-3080.	1.6	0
210	Association of improved survival (OS) and tumor control (TC) with interleukin-2 (IL2) with development of immune-related events (IREs): Data from the PROCLAIMSM registry.. Journal of Clinical Oncology, 2017, 35, 9528-9528.	1.6	0
211	Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer. IDrugs: the Investigational Drugs Journal, 2005, 8, 974-7.	0.7	0